(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 Commission File Number 001-37587 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share CTMX Nasdaq Global Select Market Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of th ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Chris Ogden - SVP, Finance & Accounting Sean McCarthy - CEO and Chairman Conference Call Participants Mitchell Kapoor - H.C. Wainwright Roger Song - Jefferies Malcolm Kuno - JP Morgan Operator Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics First Quarter 2023 Financial Results Call. Please be advised that today's call is being recorded. I would now like ...

The FDA's policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. We also cannot pred ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2022 Earnings Conference Call March 27, 2023 5:00 PM ET Company Participants Chris Ogden - SVP of Finance and Accounting Sean McCarthy - CEO and Chairman Conference Call Participants Roger Song - Jefferies Mara Goldstein - Mizuho Group Peter Lawson - Barclays Mitchell Kapoor - H.C. Wainwright Anupam Rama - JPMorgan Etzer Darout - BMO Capital Markets Operator Good day and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2022 Financial Res ...

Within 60 days following submission of the application, the FDA reviews a BLA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is acce ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Chris Ogden - SVP of Finance and Accounting Sean McCarthy - CEO and Chairman Conference Call Participants Peter Lawson - Barclays Etzer Darout - BMO Capital Markets Mara Goldstein - Mizuho Group Mitchell Kapoor - H.C. Wainwright Joseph Catanzaro - Piper Operator Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Third Quarter 2022 Financial Results Call. [Operato ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer ☐ Accelerated filer ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 27-3521219 (Stat ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Chau Cheng - Vice President of Investor Relations & Corporate Communications Sean McCarthy - Chief Executive Officer & Chairman Carlos Campoy - Chief Financial Officer Conference Call Participants Kaveri Pohlman - BTIG Etzer Darout - BMO Capital Markets Supawat Thongthip - Mizuho Mitchell Kapoor - H.C. Wainwright Operator Good afternoon, everyone. Thank you for standing by. Welcome to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer ☐ Accelerated filer ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 27-3521219 (State or ...

Destroying Cancer. Differently. © 2022 CytomX Therapeutics, Inc. Forward-Looking Statements 2 This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical and clinical pipeline and milestones, regulatory objectives, expected payments from a ...